Remdesivir and hospitalization outcomes in patients with COVID -19 in the period of SARS-CoV-2 Delta circulation

Remdesivir and hospitalization outcomes in patients with COVID -19 in the period of SARS-CoV-2 Delta circulation

Aim of the study is to analyze the effect of remdesivir on the outcome of hospitalization in patients with COVID-19 during the period of the SARS-CoV-2 Delta predominance. Material and methods. Among 11203 patients hospitalized from the pandemics start until June 2023 in the Minsk City Clinical Hosp...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. V. Litvinchuk, D. E. Danilov, I. A. Karpov
Format:	Article
Language:	Russian
Published:	Journal Infectology 2025-06-01
Series:	Журнал инфектологии
Subjects:	covid-19 sars-cov-2 delta variant remdesivir antiviral therapy
Online Access:	https://journal.niidi.ru/jofin/article/view/1791
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Remdesivir Use in Pediatric Patients with Acute SARS-CoV-2 Infection Is Safe and Well Tolerated
by: Delma J. Nieves, et al.
Published: (2025-03-01)

Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants
by: Lauren Rodriguez, et al.
Published: (2025-01-01)

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
by: Megan Neary, et al.
Published: (2024-11-01)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
by: Zi-Wei Ye, et al.
Published: (2021-01-01)

The problem of SARS-CoV-2 virus resistance to direct-acting antivirals
by: E. L. Gasich, et al.
Published: (2024-12-01)

New biothreat of JN.1 variant SARS CoV-2: viral genome, mutations and comparison with Delta and Omicron variants – a brief commentary
by: S. Kannan, et al.
Published: (2024-03-01)

Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets
by: Kuoyuan Cheng, et al.
Published: (2021-10-01)

Genome Analysis of SARS-CoV-2 Delta variant in the Kurdistan region of Iraq
by: Sevan O Majed, et al.
Published: (2024-11-01)

Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape
by: Nash D. Rochman, et al.
Published: (2022-04-01)

The Characteristics of the Delta Variant of SARS-CoV-2 Virus – the Dominant Agent of the Third and Forth Waves of Epidemic COVID-19 in Russia
by: T. E. Sizikova, et al.
Published: (2023-06-01)

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir
by: Kalpana Gupta, et al.
Published: (2025-05-01)

A comparative analysis exposes an amplification delay distinctive to SARS-CoV-2 Omicron variants of clinical and public health relevance
by: K.L. Brown, et al.
Published: (2023-12-01)

Synthesis of Radioisotope 14C Labelled Remdesivir
by: Zhi-yang YU, et al.
Published: (2025-02-01)

Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta‐Analysis
by: Saeed Khorramnia, et al.
Published: (2025-07-01)

Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology
by: Subarna Barua, et al.
Published: (2025-12-01)

Real-world effect of casirivimab and imdevimab cocktail in patients infected with SARS-CoV-2 delta and omicron variants
by: Rajas Subhash Walinjkar, et al.
Published: (2023-03-01)

Surveillance of SARS‐CoV‐2 in Pets of Harris County, Texas, Revealed More Common Pet Infections in Households With Human COVID‐19 Cases
by: Sarah J. Smith, et al.
Published: (2025-03-01)

Ensitrelvir in Hospitalized Patients with SARS-CoV-2 During the Omicron Epidemic: A Single-Center Observational Study
by: Masaya Yamato, et al.
Published: (2025-04-01)

Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19
by: Mark Berry, et al.
Published: (2025-07-01)

From Delta to Omicron—Genetic Epidemiology of SARS-CoV-2 (hCoV-19) in Southern Poland
by: Maria Miklasińska-Majdanik, et al.
Published: (2025-07-01)

An outbreak of COVID-19 after a pilgrimage to Medjugorje due to Delta sub-lineages
by: Alessandra Lo Presti, et al.
Published: (2024-03-01)

Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?
by: Darius Babusis, et al.
Published: (2025-06-01)

Emergence of Novel SARS-CoV-2 variants in India: second wave
by: Rama Adiga, et al.
Published: (2021-11-01)

SARS-CoV-2 and Coronaviruses: Understanding Transmission, Impact, and Strategies for Prevention and Treatment
by: Seyede Nafise Tabatabaei, et al.
Published: (2025-02-01)

The Effect of Carriage of <i>CYP3A5*3</i> and <i>CYP3A4*22</i> Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19
by: I. I. TEMIRBULATOV, et al.
Published: (2022-11-01)

In-hospital mortality among children and adults hospitalized with COVID-19 in Africa across pre-delta, delta, and omicron SARS-CoV-2 waves
by: Seth Inzaule, et al.
Published: (2025-08-01)

Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV
by: Vahid Rajabali Zadeh, et al.
Published: (2025-05-01)

SARS-CoV-2 Delta variant induces severe damage in the nasal cavity from the first day post-infection in the Syrian hamster model
by: Maxime Fusade-Boyer, et al.
Published: (2025-12-01)

Difference in Optical Coherence Tomography Angiography Parameters After SARS-CoV-2 Infection During the Alpha and Delta Variant Dominance Periods
by: Magdalena Kal, et al.
Published: (2024-12-01)

Neutralizing antibodies from naturally infected individuals against SARS-CoV-2 Gamma and Delta variants in the Paraguayan population
by: Angélica Samudio, et al.
Published: (2023-10-01)

The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load
by: Petr Waldauf, et al.
Published: (2025-07-01)

Antiviral efficacy of silicon nitride against SARS-CoV-2 and MERS-CoV: implications for PPE innovation
by: Brittany N. Heath, et al.
Published: (2025-08-01)

The Omicron Variant of SARS-CoV-2 Virus: the Ability to Cause Disease in Persons with Immunity against COVID-19
by: T. E. Sizikova, et al.
Published: (2023-06-01)

Protection of Prior SARS-CoV-2 Infection Against Different Variants, Including Omicron Descendants, in a Country with High Viral Transmission
by: Stefan Escobar-Agreda, et al.
Published: (2025-05-01)

Developing molecular surveillance of SARS-CoV-2 in the Czech Republic (2021–2022)
by: Timotej Šúri, et al.
Published: (2025-06-01)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
by: Hongjie Xia, et al.
Published: (2023-12-01)

The impact of SARS-CoV-2 VOCs on clinical outcomes: an overview of reviews
by: Federico Fama, et al.
Published: (2025-08-01)

Antiviral and anti-inflammatory efficacy of nanoencapsulated brazilian green propolis against SARS-CoV-2
by: Iasmin Rosanne Silva Ferreira, et al.
Published: (2025-07-01)

Molecular Docking Studies of Marine Sulfated Polysaccharides: Exploring Green Seaweed’s Role Against SARS-CoV-2 Spike Glycoprotein
by: Azalia Puspa Herida, et al.
Published: (2024-12-01)

Antiviral Activity of Kagocel<sup>®</sup> in vitro Against Virus SARS-CoV-2
by: S. Ya. Loginova, et al.
Published: (2020-06-01)